Publication

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

Authors not recorded

JCO Precis Oncol2024PMID 38603650PMC11623915stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (18)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 18

cancerDysembryoplastic Neuroepithelial Tumorcivic_curation1.00
cancerGlioblastomacivic_curation1.00
cancerIntrahepatic Cholangiocarcinomacivic_curation1.00
cancerMalignant Ovarian Brenner Tumorcivic_curation1.00
cancerSalivary Gland Adenoid Cystic Carcinomacivic_curation1.00
drugErdafitinibcivic_curation1.00
geneACOT11civic_curation1.00
geneAHCYL1civic_curation1.00
geneFGFR2civic_curation1.00
geneFGFR3civic_curation1.00
geneTACC1civic_curation1.00
geneTACC3civic_curation1.00
variantACOT11 Fusioncivic_curation1.00
variantAHCYL1 Fusioncivic_curation1.00
variantFGFR2 S252Wcivic_curation1.00
variantFGFR3 S249Ccivic_curation1.00
variantTACC1 Fusioncivic_curation1.00
variantTACC3 Fusioncivic_curation1.00

Curated evidence

Evidence citing this paper (6)

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TACC1 Fusion1
Erdafitinib	Dysembryoplastic Neuroepithelial Tumor	Predictive	C	Supports Sensitivity Response	2	accepted	EID13166 In the phase II NCI-MATCH EAY131-K2 trial, a patient with a WHO grade I dysembryoplastic neuroepithelial tumor harboring an FGFR1-TACC1 fusion had stable disease with a 24.2% maximum reduction in meas… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
TACC3 Fusion1
Erdafitinib	GlioblastomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID13165 In the phase II NCI-MATCH EAY131-K2 trial, two patients with WHO grade IV IDH1/2-wildtype glioblastoma harboring FGFR3 fusions experienced progression-free survival exceeding 168 days during erdafitin… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
ACOT11 Fusion1
Erdafitinib	Intrahepatic Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID13163 In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-ACOT11 fusion achieved a partial response to erdafitinib, with a 49.6% maximum reduction in… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
AHCYL1 Fusion1
Erdafitinib	Intrahepatic Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID13164 In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-AHCYL1 fusion achieved a partial response to erdafitinib, with a 66.7% maximum reduction in… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
FGFR3 S249C1
Erdafitinib	Malignant Ovarian Brenner Tumor	Predictive	C	Supports Sensitivity Response	3	accepted	EID13162 In the phase II NCI-MATCH EAY131-K2 trial, a patient with malignant Brenner tumor of the ovary harboring an FGFR3 S249C (p.Ser249Cys) mutation achieved a partial response to erdafitinib, with a 73.9% … (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
FGFR2 S252W1
Erdafitinib	Salivary Gland Adenoid Cystic Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID13161 In the phase II NCI-MATCH EAY131-K2 trial, a patient with high-grade adenoid cystic carcinoma of the submandibular gland harboring an FGFR2 S252W (p.Ser252Trp) mutation achieved a partial response to … (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic